Soliris contains the active ingredient eculizumab and belongs to the complement inhibitors drug class. Soliris (eculizumab) is used to treat paroxysmal nocturnal hemoglobinuria (pnh) in adults, and a rare chronic blood disease called atypical hemolytic uremic syndrome (ahus) in adults and children who weigh at least 11 pounds (5 kilograms). Eculizumab is commonly used for certain people with the following rare and serious immune problems Eculizumab may also be used for other conditions as determined by your health care provider. Eculizumab (ek yoo lye zyoo mab) treats certain blood conditions that can cause low levels of red blood cells (anemia) and blood clots, such as atypical hemolytic uremic syndrome (ahus) and paroxysmal nocturnal hemoglobinuria (pnh). Eculizumab is a humanised monoclonal (igg2/4κ) antibody produced in ns0 cell line by recombinant dna technology
One vial of 30 ml contains 300 mg of eculizumab (10 mg/ml) For the full list of excipients, see section 6.1 Concentrate for solution for infusion. Know about technical details of soliris like Chemical name, chemistry structure, formulation, uses, toxicity, action, side effects and more at pharmacompass.com. Soliris, a complement inhibitor, is a formulation of eculizumab which is a recombinant humanized monoclonal igg2/4 antibody produced by murine myeloma cell culture and purified by standard bioprocess technology.
Soliris is a biologic medication A biologic is made from parts of living organisms
OPEN
